+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Age-Related Macular Degeneration (AMD) Therapeutics Market by Type and Geography - Global Forecast 2019-2023 - Product Image

Age-Related Macular Degeneration (AMD) Therapeutics Market by Type and Geography - Global Forecast 2019-2023

  • ID: 4801810
  • Report
  • Region: Global
  • 125 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
Global Age-Related Macular Degeneration (AMD) Therapeutics Market: About this market

Age-related macular degeneration (AMD) is a bilateral ocular disease that affects the central area of the retina known as the macula. This age-related macular degeneration considers sales from both wet AMD, dry AMD. Our analysis also considers the sales of AMD in Asia, Europe, North America and ROW. In 2018, the wet AMD segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increasing use of VEGF inhibitors, which are used for the treatment of wet AMD will play a significant role in the wet AMD segment to maintain its market position. Also, our global age-related macular degeneration market report also looks at factors such as high prevalence of AMD, strong pipeline and expected approvals, and rising geriatric populations. However, lack of approved therapies for dry AMD, introduction of biosimilars, side effects of available therapeutics may hamper the growth of the age-related macular degeneration industry over the forecast period.

Global Age-Related Macular Degeneration (AMD) Therapeutics Market: Overview

High prevalence of AMD

The prevalence of AMD is extremely high, owing to the presence of high-risk factors for developing the condition. Risk factors such as aging, smoking, high cholesterol, and high blood pressure are the major contributors to the development of AMD. Moreover, despite the high prevalence of AMD, no approved therapies are available in the market for the treatment of the condition. Thus, the high prevalence coupled with the huge unmet medical need of dry AMD is expected to drive the market at a CAGR of over 8% during the forecast period.

Development of gene therapy for AMD

There is a huge unmet need for safe and novel drugs to treat AMD. The currently available anti-VEGF therapies require repetitive and inconvenient intraocular injections. Owing to factors such as inconvenience and discomfort associated with frequent injections in the eye, patient compliance is a significant concern with anti-VEGF therapies. Hence, several companies are working on novel drugs against AMD, among which gene therapy is expected to cure the disease effectively. Hence, the development of gene therapy is expected to be a positive trend for the global AMD therapeutics market.

Competitive Landscape

With the presence of few major players, the global age-related macular degeneration (AMD) therapeutics market is moderately concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading age-related macular degeneration manufacturers, that include Amgen Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Regeneron Pharmaceuticals Inc.

Also, the age-related macular degeneration market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Wet AMD - Market size and forecast 2018-2023
  • Dry AMD - Market size and forecast 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Strategic alliances
  • Development of gene therapy for AMD
  • Growing awareness about AMD
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Wet AMD - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Wet AMD - Year-over-year growth 2019-2023 (%)
Exhibit 21: Dry AMD - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Phase III drugs for dry AMD
Exhibit 23: Cell therapies under development for dry AMD
Exhibit 24: Dry AMD - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Population aged 65 years and above (% of total) in Asia 2017
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Some late-stage drugs for treatment of AMD
Exhibit 45: Global growth in geriatric population 2013-2017 (%)
Exhibit 46: Approximate cost of AMD drugs
Exhibit 47: Companies developing biosimilars: Overview
Exhibit 48: Side effects associated with drugs used for AMD
Exhibit 49: Impact of drivers and challenges
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: Amgen Inc. - Vendor overview
Exhibit 56: Amgen Inc. - Business segments
Exhibit 57: Amgen Inc. - Organizational developments
Exhibit 58: Amgen Inc. - Geographic focus
Exhibit 59: Amgen Inc. - Key offerings
Exhibit 60: Amgen Inc. - Key customers
Exhibit 61: Bausch Health Companies Inc. - Vendor overview
Exhibit 62: Bausch Health Companies Inc. - Business segments
Exhibit 63: Bausch Health Companies Inc. - Organizational developments
Exhibit 64: Bausch Health Companies Inc. - Geographic focus
Exhibit 65: Bausch Health Companies Inc. - Segment focus
Exhibit 66: Bausch Health Companies Inc. - Key offerings
Exhibit 67: Bausch Health Companies Inc. - Key customers
Exhibit 68: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 69: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 70: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 71: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 72: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 73: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 74: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 75: Novartis AG - Vendor overview
Exhibit 76: Novartis AG - Business segments
Exhibit 77: Novartis AG - Organizational developments
Exhibit 78: Novartis AG - Geographic focus
Exhibit 79: Novartis AG - Segment focus
Exhibit 80: Novartis AG - Key offerings
Exhibit 81: Novartis AG - Key customers
Exhibit 82: Regeneron Pharmaceuticals Inc. - Vendor overview
Exhibit 83: Regeneron Pharmaceuticals Inc. - Business segments
Exhibit 84: Regeneron Pharmaceuticals Inc. - Organizational developments
Exhibit 85: Regeneron Pharmaceuticals Inc. - Geographic focus
Exhibit 86: Regeneron Pharmaceuticals Inc. - Key offerings
Exhibit 87: Regeneron Pharmaceuticals Inc. - Key customers
Exhibit 88: Validation techniques employed for market sizing
Exhibit 89: Definition of market positioning of vendors


Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
The following companies are recognised as the key players in the global automotive steering lock system market: Amgen Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Regeneron Pharmaceuticals Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of gene therapy for AMD.”

According to the report, one of the major drivers for this market is the high prevalence of AMD.

Further, the report states that one of the major factors hindering the growth of this market is the side effects of available therapeutics.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Amgen Inc.
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
Adroll
adroll